Corel Medical Series: Cancer/Corel Medical Series: Cancer.iso/mac/Program/Indexdat/indexc.H

Text File | 1997-01-27 | 4KB | 2 lines

Hair loss,2,Hairy cell leukemia,c18.27,Hallucinogens and sexuality,p23.9,Haloperidol,chr.p17.14,Halsted radical mastectomy,c06.19,Hashimoto's thyroidids,c42.5,Head diagram,c14a.2,Head and neck cancer,12,Headache,p20.5,Health care team,p03.1,Health and Welfare Canada Drugs Directorate Clinical trials,p04.21,Healthy People 2000 Objectives,p33.4;chr.p34.2,Heartburn,p06.19,Heel and elbow protectors,p26.5,Hemangioendothelioma,c19.1;c19.17,Hematogenous spread,p01.10,Hematologist,p03.4;p07.9,Hematoporphyrin,p09.4;p09.10;c04.18;c37.19,Hemodilution,p14.10,Heparin,p07.10,Hepatitis,p14.3;p14.12;c19.2,Hepatoblastoma,c10a.2,Heredity,7,Herpes simplex,c09.5,Herpes zoster,p20.4,Hexamethylmelamine,c29.20;c29.23,High Linear Energy Transfer (LET) radiation,p06.15,Histamine receptor blockers,c15.11,Histiocytosis X,c10a.2,HLA typing,p12.5;p12.24;p14.5,Hodgkin's disease,19,Home care,9,Home care nurse,p15.11,Homeopathy,p13.16,Hope,p29.7;p30.7;p32.8,Hormonal therapy,10,Hormones,3,Hospice nurse,p15.11,Hospital attendant,p15.8,Hospital staff nurse,p15.8,Hoxsey Treatment,p13.5,HTLV I,p14.3,Human immunodeficiency virus (HIV),6,Human papilloma virus (HPV),5,Humoral immunity,p20.2,Hybridoma,p08.14,Hydatidiform mole,c43.2;c43.13;c43.17,Hydromorphone,p19.8,Hydroxyurea,chr.p17.13;p35.17;c18.13,Hyperalimentation,p18.13,Hypercalcemia,c28.17;c32.9,Hyperfractionation,p06.15,Hypertension,c45.4,Hyperthermia,6,Hyperthermic perfusion therapy,6,Hyperthyroidism,c41.2,Hyperviscosity,c28.19,Hypopharynx tumor,c14a.2;c14a.7;c14b.29,Hypophysectomy,c05.20;c34.5,Hypopituitarism,c41.2,Hysterectomy,6,
causes,p06.20;p07.26;p17.38,reducing,p17.38,child,c10a.7,diagnosis,c14a.8,investigational drugs,p35.12,questions to ask,c14b.44,recurrence,c14b.7;c14b.13;c14b.19;c14b.23;c14b.28;c14b.32;c14b.39;c14b.43,risk factors,c14a.5,screening,c14a.6,staging,c14a.9,symptoms,c14a.7,treatment,c14b.2,types,c14a.1,unknown primary site,c07.1;c07.11;c14b.41,bone and soft tissue sarcomas,c36.6,breast cancer,c06.4,childhood cancers,c10c.1,colorectal cancer,c11a.3,ovarian cancer,c29.4,risk factor,p01.8;p34.5,thyroid cancer,c42.4,causes,c23.5,child,c10a.2;c10a.7,diagnosis,c23.9,follow-up,c23.19,investigational drugs,p35.12,Iymphocyte depletion,c23.4,Iymphocyte predominant,c23.3,mixed cellularity,c23.3,questions to ask,c23.22,recurrence,c23.21,risk factors,c23.6,screening,c23.7,and sexuality,p23.7,spread,c23.4,staging,c23.11,symptoms,c23.8,treatment,p12.19;c23.13,types,p01.13;c23.2,unknown primary site,c07.1,body care,p26.8,choosing,p26.2,costs,p26.7,emergencies,p26.17,equipment,p26.4,pain control,p26.12,planning,p26.3,support services,p26.15,treatment services,p26.7,after pituitary cancer,c34.8,after treatment,p23.10,drug selection,p23.20,for brain cancer,c05.27,for breast cancer,REC.15;c06.26;c06.41;c06.46,for gynecological tumor,p23.6,for prostate cancer,c35.17,for uterine cancer,c44.12,risk factor,c19.3;c44.3,side effects,p23.23,in chemotherapy,p07.6,promote cancer,p01.7,risk factor,c35.4,childhood cancer,c10a.5,Kaposi's sarcoma,c16.3,Iymphoma,c24.4;c22.1,risk factor,c24.5;c37.5;c40.4,skin cancer,c37.5,testis cancer,c40.4,anal cancer,c02.3,cervical cancer,c09.2,penile cancer,c33.2,vaginal cancer,c46.2,vulvar cancer,c47.2,choosing,p10.6,for cervical cancer,c09.20,for vaginal cancer,c46.10,how it works,p10.3,in combination therapy,p06.14;p10.3,side effects,p10.5,choosing,p11.3,defined,p11.1,drugs used,p11.5,how it works,p11.6,illustration,p11.6,side effects,p11.8,cervix cancer,c09.15,endometrial carcinoma,c44.9,ovarian cancer,c29.16;c30.12,and sexuality,p23.6,trophoblastic disease,c43.9,uterine sarcoma,c45.10,